Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 9, 2021

Novartis’ canakinumab fails to meet primary endpoint in lung cancer trial

Novartis has reported that the Phase III CANOPY-2 study of canakinumab (ACZ885) in combination with the chemotherapy agent docetaxel failed to meet the primary endpoint of overall survival (OS) in patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Novartis has reported that the Phase III CANOPY-2 study of canakinumab (ACZ885) in combination with the chemotherapy agent docetaxel failed to meet the primary endpoint of overall survival (OS) in patients with advanced or metastatic non-small cell lung cancer (NSCLC).

A human monoclonal antibody, canakinumab is an interleukin-1beta (IL-1β) inhibitor of pro-tumour inflammation (PTI) in NSCLC.

The trial enrolled 237 adult subjects with locally advanced or metastatic NSCLC whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy

It analysed the role of canakinumab plus docetaxel in second- or third-line therapy as compared with docetaxel alone in NSCLC.

Part I of the trial was a previously reported safety run-in study to analyse appropriate dosage while Part 2 assessed OS.

Novartis chief medical officer and Global Drug Development head John Tsai said: “While results from the CANOPY-2 trial are not what we hoped for in patients with advanced or metastatic non-small cell lung cancer who have been treated with other lines of therapy, these data give us valuable insights into IL-1β inhibition.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“Ongoing Phase III studies in non-small cell lung cancer continue, evaluating canakinumab in earlier treatment settings.”

The company expects to report final results from a Phase III CANOPY-1 study analysing canakinumab as first-line therapy for locally advanced or metastatic NSCLC plus pembrolizumab (immunotherapy) and platinum-based doublet chemotherapy before the year-end.

Another Phase III CANOPY-A study is assessing canakinumab in the adjuvant setting after surgical resection and cisplatin-based chemotherapy for preventing cancer relapse. It has so far enrolled over 950 subjects and is anticipated to enrol a total of 1,500 participants.

Accounting for approximately 85% of lung cancer diagnoses, NSCLC results in nearly 1.7 million new cases every year. At present, the five-year survival rate is less than 20% for lung cancer, which lowers further when detected at later stages.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU